Insider Trading March 23, 2026

OraSure CEO Purchases $94,597 in Shares as Activist Pressure Builds

Carrie Eglinton Manner increases her stake through a Rule 10b5-1 plan amid mixed financial results and board nominations from a 5% holder

By Marcus Reed OSUR
OraSure CEO Purchases $94,597 in Shares as Activist Pressure Builds
OSUR

OraSure Technologies Inc President and CEO Carrie Eglinton Manner bought 32,300 shares on March 20, 2026, in a transaction valued at $94,597, according to a Form 4 filed with the SEC. The acquisition, carried out under a pre-arranged Rule 10b5-1 plan adopted in November 2025, brings her direct holdings to 2,190,874 shares. The move comes as the company reports a Q4 2025 revenue shortfall, improvements in gross margins, ongoing operational losses, and activist pressure from a 5% shareholder seeking board changes ahead of the 2026 annual meeting.

Key Points

  • CEO Carrie Eglinton Manner purchased 32,300 shares on March 20, 2026, for $94,597 at a weighted average price of $2.9287 per share, with per-share prices ranging from $2.86 to $2.98.
  • Following the purchase, the CEO directly holds 2,190,874 shares; the stock traded at $3.08 and is up 27% year-to-date, with InvestingPro Fair Value analysis indicating the shares appear undervalued.
  • OraSure reported Q4 2025 revenue of $26.8 million, missing the expected $28.08 million by about 4.6%, while noting improved gross margins but still facing operational losses and a difficult funding environment.

OraSure Technologies Inc (NASDAQ:OSUR) reported an insider purchase by President and CEO Carrie Eglinton Manner on March 20, 2026, as documented in a Form 4 filing with the Securities and Exchange Commission. The filing shows Manner acquired 32,300 shares of common stock at a weighted average price of $2.9287 per share. Individual trade prices recorded in the filing ranged from $2.86 to $2.98, for a total transaction cost of $94,597.

Following the transaction, Manner's direct ownership in OraSure stands at 2,190,874 shares. At the time of reporting, the companys stock was trading at $3.08, registering a 27% gain year-to-date. InvestingPro Fair Value analysis cited in company-related commentary indicates the shares appear undervalued relative to that assessment.

The purchase was conducted pursuant to a pre-arranged Rule 10b5-1 trading plan that Manner adopted on November 29, 2025. The Form 4 filing confirms the trade executed under that plan and aligns with commentary from InvestingPro noting active repurchases by management. InvestingPro also highlights further investor tools, including ProTips and Pro Research Reports that cover OSUR and more than 1,400 U.S. equities.

These insider buying details arrive against a backdrop of mixed operational performance. OraSure reported fourth-quarter 2025 revenue of $26.8 million, below the consensus expectation of $28.08 million by approximately 4.6%. The company indicated improvements in gross margins in its quarterly disclosure, while also acknowledging persistent operational losses and a challenging funding environment.

Looking ahead, the company has planned product launches in 2026 that market commentary suggests could contribute to future growth, though no additional performance guarantees are provided. Separately, Altai Capital Management, which holds about a 5% stake in OraSure, has publicly sought changes to the company's board. Altai has nominated Rishi Bajaj and John Bertrand for board seats to be voted on at the 2026 annual shareholder meeting, reflecting active investor engagement in corporate governance.

Combined, the CEO's purchase, the company's recent quarterly results, upcoming product plans, and mounting shareholder activism create a complex picture for stakeholders watching OraSure. The Form 4 disclosure provides a precise accounting of the transaction, while the broader corporate developments underscore continuing strategic and financial challenges that market participants will track into 2026.


Disclosure: The article summarizes publicly filed information and company-reported results. No additional disclosure is included in the article body.

Risks

  • Operational losses and a strained funding environment could affect the companys ability to execute product launches and strategic plans - this has implications for investors and the broader healthcare equipment and diagnostics sector.
  • Revenue for Q4 2025 fell short of expectations by approximately 4.6%, introducing near-term performance uncertainty that may influence capital markets sentiment toward the stock.
  • Active shareholder engagement from Altai Capital Management, which holds a 5% stake and has nominated board candidates, presents governance uncertainty ahead of the 2026 annual meeting.

More from Insider Trading

Immunome Director Disposes $1.34M in Shares Across Two Trades Mar 23, 2026 NextNav Accounting Chief Disposes of $32,000 in Stock; Receives New Grants and Options Mar 23, 2026 ChargePoint CRO Sells Small Stake as Company Posts Revenue Growth, Continued Losses Mar 23, 2026 ChargePoint General Counsel Sells $14,283 in Stock as Company Navigates Growth and Losses Mar 23, 2026 ChargePoint Executive Sells Small Stake to Cover Taxes as Company Posts Q4 Revenue Gain Mar 23, 2026